The U.S. Food and Drug Administration has reportedly issued a formal warning letter to Pfizer over a 2017 video promoting Estring, a treatment for painful postmenopausal sex.
According to an MM&M report, the federal agency says the video failed to communicate risk information and includes misleading efficacy claims.
While a patient speaking with her physician in the video (who both, according to MM&M, were Pfizer spokespeople) says she experienced no side effects while taking Estring, the FDA says the statement suggests patients should expect the same experience.
Another issue, the FDA says, is toward the end of the video where the doctor fails to mention potential adverse effects when the patient asks, “Is there anything we didn’t cover in the interview?”
To read more on MM&M, click here.